JP2015518000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015518000A5 JP2015518000A5 JP2015505934A JP2015505934A JP2015518000A5 JP 2015518000 A5 JP2015518000 A5 JP 2015518000A5 JP 2015505934 A JP2015505934 A JP 2015505934A JP 2015505934 A JP2015505934 A JP 2015505934A JP 2015518000 A5 JP2015518000 A5 JP 2015518000A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- adenine
- fluorouracil
- orotic acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 14
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 7
- 229930024421 Adenine Natural products 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 229960000643 adenine Drugs 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 229960005010 orotic acid Drugs 0.000 claims 7
- 239000000758 substrate Substances 0.000 claims 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229960002949 fluorouracil Drugs 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 230000001681 protective effect Effects 0.000 claims 6
- 206010059024 Gastrointestinal toxicity Diseases 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940126701 oral medication Drugs 0.000 claims 3
- 230000003204 osmotic effect Effects 0.000 claims 3
- 229940126409 proton pump inhibitor Drugs 0.000 claims 3
- 239000000612 proton pump inhibitor Substances 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/446,328 US8653090B2 (en) | 2008-03-12 | 2012-04-13 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
| US13/446,328 | 2012-04-13 | ||
| PCT/US2013/036326 WO2013155385A1 (en) | 2012-04-13 | 2013-04-12 | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015518000A JP2015518000A (ja) | 2015-06-25 |
| JP2015518000A5 true JP2015518000A5 (enrdf_load_stackoverflow) | 2016-06-09 |
Family
ID=49328189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505934A Pending JP2015518000A (ja) | 2012-04-13 | 2013-04-12 | 癌の化学療法剤の投与に関連した副作用の処置のための組成物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2836217A4 (enrdf_load_stackoverflow) |
| JP (1) | JP2015518000A (enrdf_load_stackoverflow) |
| CN (1) | CN104394872A (enrdf_load_stackoverflow) |
| IN (1) | IN2014DN09546A (enrdf_load_stackoverflow) |
| WO (1) | WO2013155385A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736557B2 (en) | 2016-03-30 | 2020-08-11 | Brain F.I.T. Imaging, LLC | Methods and magnetic imaging devices to inventory human brain cortical function |
| CA3077705A1 (en) | 2017-10-03 | 2019-04-11 | Braint F.I.T. Imaging, Llc | Methods and magnetic imaging devices to inventory human brain cortical function |
| EP3946034A4 (en) | 2019-04-03 | 2023-01-11 | Brain F.I.T. Imaging, LLC | MAGNETIC IMAGING METHODS AND DEVICES FOR EXAMINING HUMAN BRAIN CORTICAL FUNCTION |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6130035A (en) * | 1998-02-20 | 2000-10-10 | Brusilow Enterprise Llc | Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening |
| US6995165B2 (en) * | 2002-02-12 | 2006-02-07 | Ford John P | Methods, compositions, and kits for organ protection during systemic anticancer therapy |
| US6979688B2 (en) * | 2002-02-12 | 2005-12-27 | Ford John P | Treatment method against side-effects of chemotherapy |
| GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
| US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
| US7470672B2 (en) * | 2006-07-31 | 2008-12-30 | Savvipharm Inc. | Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives |
-
2013
- 2013-04-12 EP EP13775759.7A patent/EP2836217A4/en not_active Withdrawn
- 2013-04-12 WO PCT/US2013/036326 patent/WO2013155385A1/en active Application Filing
- 2013-04-12 JP JP2015505934A patent/JP2015518000A/ja active Pending
- 2013-04-12 CN CN201380031029.XA patent/CN104394872A/zh active Pending
-
2014
- 2014-11-13 IN IN9546DEN2014 patent/IN2014DN09546A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1998762T3 (pl) | Stałe postacie dawkowania zawierające składnik czynny o zamaskowanym smaku | |
| ES2545395T3 (es) | Asociación de ivermectina con brimonidina para el tratamiento o prevención de la rosácea | |
| JP2016539921A5 (enrdf_load_stackoverflow) | ||
| WO2007095600A3 (en) | Disintegrable oral films | |
| JP2016534153A5 (enrdf_load_stackoverflow) | ||
| WO2006044421A3 (en) | Cardiac safe, rapid medication delivery | |
| JP2008044951A5 (enrdf_load_stackoverflow) | ||
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| IN2014CN02592A (enrdf_load_stackoverflow) | ||
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| JP2015531377A5 (enrdf_load_stackoverflow) | ||
| JP2009522376A5 (enrdf_load_stackoverflow) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| MX2021014029A (es) | Formulaciones, fabricación y usos de imatinib. | |
| JP2011516497A5 (enrdf_load_stackoverflow) | ||
| JP2013523676A5 (enrdf_load_stackoverflow) | ||
| ATE554770T1 (de) | Therapeutisches mittel gegen entzündliche darmerkrankungen | |
| MY157187A (en) | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance | |
| JP2017532316A5 (enrdf_load_stackoverflow) | ||
| JP2015518000A5 (enrdf_load_stackoverflow) | ||
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| JP2021107464A (ja) | 眼科組成物 |